Skip to main content
SpringerLink
Log in

Newer clinically available antithrombotics and their antidotes

  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

New oral anticoagulants (NOACs) have emerged as an alternative therapy to warfarin in the treatment of arterial and venous thromboembolism and in stroke prevention in patients with non-valvular atrial fibrillation (AF). Three of them, i.e., dabigatran, rivaroxaban, and apixaban, have been approved for clinical use in North America and in a number of European countries. In non-valvular AF, their approval was based on large randomized trials showing that they are non-inferior or even, in some instances, superior to warfarin. Dabigatran is a direct thrombin (factor IIa) inhibitor; rivaroxaban and apixaban are direct factor Xa inhibitors. Before using NOACs, it is recommended to become familiar with their pharmacological characteristics and their metabolism. The absence of specific antidotes is often cited as part of the possible weaknesses of NOACs. Antidotes are perceived to be useful in emergency situations such as life-threatening bleeding or non-elective major surgery. NOACs do not require blood monitoring, and therefore, patient compliance to the treatment is essential. For the present time, there are no specific antidotes available for the three NOACs approved for clinical use. However, phase I or phase II research studies in this area are ongoing. For dabigatran, a specific antidote has been tested in a rat model of anticoagulation, and a study in healthy male volunteers has been recently reported. For rivaroxaban, prothrombin complex concentrates (PCCs) have been found to completely reverse the prolongation of the prothrombin time induced by this NOAC. For apixaban, recombinant factor VII was found in an experimental study using human blood to be superior to activated PCC (aPCC) and PCC. More specific antidotes for rivaroxaban and apixaban are in phases I and II evaluation. The management of patients suffering from a major bleeding or requiring a non-elective major surgery includes non-specific reversal agents and is discussed in the light of a recent position paper and of current literature. Most recommendations are based on expert opinions only as randomized trials using agents for reversal of anticoagulation in case of life-threatening bleeding or of major urgent surgery are not available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361, 1139–1151.

    Article  CAS  PubMed  Google Scholar 

  2. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine, 365(10), 883–891.

    Article  CAS  PubMed  Google Scholar 

  3. Granger, C. B., Alexander, J. H., McMurray, J. J., Lopes, R. D., Hylek, E. M., Hanna, M., et al. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 15(36), 981–992.

    Article  Google Scholar 

  4. Hankey, G. J., & Eikelboom, J. W. (2011). Dabigatran etexilate: a new oral thrombin inhibitor. Circulation, 123, 1436–1450.

    Article  PubMed  Google Scholar 

  5. Fox, K. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., et al. (2011). Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal, 32, 2387–2394.

    Article  CAS  PubMed  Google Scholar 

  6. Wallentin, L., Lopes, R. D., Hanna, M., Thomas, L., Hellkamp, A., Nepal, S., et al. (2013). Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation, 127, 2166–2176.

    Article  CAS  PubMed  Google Scholar 

  7. Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., et al. (2013). European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 15, 625–651.

    Article  PubMed  Google Scholar 

  8. Usman, M. H., Notaro, L. A., Patel, H., & Ezekowitz, M. D. (2008). New developments in anticoagulation for atrial fibrillation. Current Treat Options Cardiovascular Medicine, 10, 388–397.

    Article  Google Scholar 

  9. Piccini, J. P., Lopes, R. D., & Mahaffey, K. W. (2010). Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Current Opinion in Cardiology, 25, 312–320.

    Article  PubMed  Google Scholar 

  10. Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., et al. (2013). A specific antidote for dabigatran: functional and structural characterization. Blood, 121, 3554–3562.

    Article  CAS  PubMed  Google Scholar 

  11. Millar, C. M., & Lane, D. A. (2013). Blocking direct inhibitor bleeding. Blood, 121, 3543–3544.

    Article  CAS  PubMed  Google Scholar 

  12. Van Ryn, J., Stangier, J., Haertter, S., Liesenfeld, K. H., Wienen, W., Feuring, M., et al. (2010). Dabigatran etexilate—novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis & Haemostasis, 103, 1116–1127.

    Article  Google Scholar 

  13. Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M., Meijers, J. C., Buller, H. R., & Levi, M. (2011). Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. A randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 124, 1573–1579.

    Article  CAS  PubMed  Google Scholar 

  14. Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Cracowski, J. L., & Pernod, G. (2012). Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thrombosis & Haemostasis, 108, 217–224.

    Article  CAS  Google Scholar 

  15. Makris, M., Van Veen, J. J., Tait, C. R., Mumford, A. D., & Laffan, M. (2013). British Committee for Standards in Hematology Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology, 160, 35–46.

    Article  CAS  PubMed  Google Scholar 

  16. Pujadas-Mestres, L., Escolar, G., Arellano-Rodrigo, E., & Galán, A. M. (2013). Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Drugs of Today (Barcelona, Spain), 49, 425–436.

    Article  CAS  Google Scholar 

  17. Crowther, M. A., Ageno, W., Garcia, D., Wang, L., Witt, D. M., Clark, N. P., et al. (2009). Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Annals of Internal Medicine, 150, 293–300.

    Article  PubMed  Google Scholar 

  18. Lu, G., De Guzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K., Lee, G., et al. (2013). A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Medicine, 19, 446–451.

    Article  CAS  PubMed  Google Scholar 

  19. Sarode, R., Milling, T. J., Refaai, M. A., et al. (2013). Efficacy and safety of a 4-factor prothrombin Complex concentrate in patients on vitamin K antagonists presenting with major bleeding. A randomized, plasma-controlled, phase IIb study. Circulation, 128, 1234–1241.

    CAS  PubMed  Google Scholar 

  20. Boehringer Ingelheim Pharmaceuticals. Study to evaluate the safety, pharmacokinetics and pharmacodynamics of BI 655075 administered alone or with dabigatran etexilate. http://clinicaltrials.gov/show/NCT01688830. Accessed 8 May 2013.

  21. Portola Pharmaceuticals, 2013. PRT4445: FXa inhibitor antidote. http://www.portola.com/PRT4445-Fxa-Inhibitor-Antidote. Accessed 8 May 2013.

  22. Portola Pharmaceuticals. Phase 2 healthy volunteer studies to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. http://clinicaltrials.gov/show/NCT01758432. Accessed 8 May 2013.

  23. Pfizer Press Release, Nov 1 2012. Portola, Bristol-Myers Squibb and Pfizer sign clinical collaboration agreement to study ELIQUIS® and Portola’s universal factor Xa inhibitor antidote PRT4445. http://press.pfizer.com/press-release/portola-bristol-myers-squibb-and-pfizer-sign-clinical-collaboration-agreement-study-el.

  24. Janssen Press Release, Feb 5 2013. XARELTO® to be studied with factor Xa inhibitor antidote. http://www.janssenpharmaceuticalsinc.com/assets/P2_Antidote_Study_Press%20Release_Janssen_FINAL.pdf.

  25. Janssen Research & Development, LLC. A study to assess the effects of 2 different prothrombin complex concentrates on the pharmacodynamics of rivaroxaban in healthy adult volunteers. http://clinicaltrials.gov/show/NCT01656330. Accessed 8 May 2013.

  26. Pernod, G., Albaladejo, P., Godier, A., et al. (2013). Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP)-March 2013. Archives of Cardiovascular Diseases, 106, 382–393.

  27. Holster, L., Hunfeld, N. G. M., Kuipers, E. J., Kruip, M. J. H. A., & Tjwa, E. T. T. L. (2013). On the treatment of new oral anticoagulant-associated gastrointestinal hemorrhage. Journal of Gastrointestinal and Liver Diseases, 22, 229–231.

  28. Crowther, M. A., & Warkentin, T. E. (2009). Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. Journal of Thrombosis and Haemostasis, 7(Suppl 1), 107–110.

Download references

Conflict of interest

There is no conflict of interest to disclose.

Author information

Authors and Affiliations

  1. Aix-Marseille Université, 2 Place Delibes, 13008, Marseille, France

    Samuel Lévy

Authors
  1. Samuel Lévy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel Lévy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lévy, S. Newer clinically available antithrombotics and their antidotes. J Interv Card Electrophysiol 40, 269–275 (2014). https://doi.org/10.1007/s10840-014-9910-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-014-9910-2

Keywords

Search

Navigation